α-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors

Vaccine

Volumn 26, Issue 46, 2008, Pages 5855-5863

  Choi, Youn Seok ^a,b   Hoory, Talia ^a   Monie, Archana ^a   Wu, Annie ^a   Connolly, Denise ^c   Hung, Chien Fu ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b The Catholic University of Korea   (South Korea)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

Galactosylceramide; Adjuvant; MOSEC; Ovarian; Tumor cell based vaccines

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; MUELLERIAN INHIBITING FACTOR; TUMOR CELL VACCINE; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; EPITHELIUM CELL; EPITHELIUM TUMOR; FEMALE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; SURVIVAL; TRANSGENIC MOUSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL SURVIVAL; CYTOKINES; FEMALE; FLOW CYTOMETRY; GALACTOSYLCERAMIDES; INTERFERON-GAMMA; LYMPHOCYTE SUBSETS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 53449099910     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.08.027     Document Type: Article

References (26)

1. Greenlee R.T., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 2000. CA Cancer J Clin 50 January-February (1) (2000) 7-33
2. Coukos G., Conejo-Garcia J.R., Roden R.B., and Wu T.C. Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther 5 September (9) (2005) 1193-1210
3. Thompson P.L., and Dessureault S. Tumor cell vaccines. Adv Exp Med Biol 601 (2007) 345-355
4. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 188 October (2002) 147-154
5. Antonia S.J. B7-1 gene-modified tumor cell vaccines. Curr Opin Mol Ther 1 February (1) (1999) 50-56
6. Kobayashi E., Motoki K., Uchida T., Fukushima H., and Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 7 10-11 (1995) 529-534
7. Nakagawa R., Motoki K., Ueno H., Iijima R., Nakamura H., Kobayashi E., et al. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. Cancer Res 58 March (6) (1998) 1202-1207
8. Burdin N., Brossay L., Koezuka Y., Smiley S.T., Grusby M.J., Gui M., et al. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes. J Immunol 161 October (7) (1998) 3271-3281
9. Spada F.M., Koezuka Y., and Porcelli S.A. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 188 October (8) (1998) 1529-1534
10. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278 November (5343) (1997) 1626-1629
11. Chung Y., Qin H., Kang C.Y., Kim S., Kwak L.W., and Dong C. An NKT-mediated autologous vaccine generates CD4 T cell-dependent potent anti-lymphoma immunity. Blood June (2007)
12. Shimizu K., Goto A., Fukui M., Taniguchi M., and Fujii S. Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J Immunol 178 March (5) (2007) 2853-2861
13. Youn H.J., Ko S.Y., Lee K.A., Ko H.J., Lee Y.S., Fujihashi K., et al. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine 25 July (28) (2007) 5189-5198
14. Nagaraj S., Ziske C., Strehl J., Messmer D., Sauerbruch T., and Schmidt-Wolf I.G. Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo. Int Immunol 18 August (8) (2006) 1279-1283
15. Silk J.D., Hermans I.F., Gileadi U., Chong T.W., Shepherd D., Salio M., et al. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest 114 December (12) (2004) 1800-1811
16. Connolly D.C., Bao R., Nikitin A.Y., Stephens K.C., Poole T.W., Hua X., et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 63 March (6) (2003) 1389-1397
17. Roby K.F., Taylor C.C., Sweetwood J.P., Cheng Y., Pace J.L., Tawfik O., et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21 April (4) (2000) 585-591
18. Hung C.F., Calizo R., Tsai Y.C., He L., and Wu T.C. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine 25 January (1) (2007) 127-135
19. Hung C.F., Tsai Y.C., He L., and Wu T.C. Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8(+) T cells. Gene Ther 14 June (12) (2007) 921-929
20. Hayakawa Y., Takeda K., Yagita H., Kakuta S., Iwakura Y., Van Kaer L., et al. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide. Eur J Immunol 31 June (6) (2001) 1720-1727
21. Chang C.L., Wu T.C., and Hung C.F. Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther 14 August (16) (2007) 1189-1198
22. Kim D., Hung C.F., and Wu T.C. Monitoring the trafficking of adoptively transferred antigen-specific CD8-positive T cells in vivo, using noninvasive luminescence imaging. Hum Gene Ther June (2007)
23. Fujii S., Shimizu K., Kronenberg M., and Steinman R.M. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 3 September (9) (2002) 867-874
24. Wilson M.T., Johansson C., Olivares-Villagomez D., Singh A.K., Stanic A.K., Wang C.R., et al. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA 100 September (19) (2003) 10913-10918
25. Chen H., and Paul W.E. Cultured NK1.1+ CD4+ T cells produce large amounts of IL-4 and IFN-gamma upon activation by anti-CD3 or CD1. J Immunol 159 September (5) (1997) 2240-2249
26. Ko S.Y., Ko H.J., Chang W.S., Park S.H., Kweon M.N., and Kang C.Y. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 175 September (5) (2005) 3309-3317